Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle
Launched by SHAARE ZEDEK MEDICAL CENTER · Mar 19, 2007
Trial Information
Current as of June 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- * Primary or secondary infertility due to:
- • Ovulatory dysfunction
- • Mild male infertility
- • Unexplained infertility
- • Endometrium \< 6 mm at time of hCG during previous treatment with clomiphene citrate
- • Age 18-35
- Exclusion Criteria:
- • Serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate
About Shaare Zedek Medical Center
Shaare Zedek Medical Center, a leading healthcare institution located in Jerusalem, Israel, is dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in medical services, the center integrates cutting-edge technology with compassionate healthcare practices. With a multidisciplinary team of experienced researchers and clinicians, Shaare Zedek actively participates in various clinical trials aimed at exploring new treatments and therapies across multiple medical disciplines. The center prioritizes patient safety, ethical standards, and scientific rigor, ensuring that all research conducted aligns with the highest benchmarks of clinical excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Avi Tsafrir, MD
Principal Investigator
Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Jerusalem, Israel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials